Gilead Sciences Inc. (GILD) News

Gilead Sciences Inc. (GILD): $62.48

0.27 (+0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GILD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter GILD News Items

GILD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GILD News Highlights

  • GILD's 30 day story count now stands at 74.
  • Over the past 24 days, the trend for GILD's stories per day has been choppy and unclear. It has oscillated between 1 and 16.
  • The most mentioned tickers in articles about GILD are DRUG, RAIN and MG.

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

3 Moonshot Stocks Insiders Are Buying. What Do They Know?

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares.

Thomas Yeung on InvestorPlace | February 25, 2022

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Yahoo | February 25, 2022

Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)

By Derek Major

Yahoo | February 24, 2022

Tesla Is Just One Reason Why Stocks Are Actually 21% Cheaper Now

Curious just how much cheaper the S&P 500 is now due to the sell-off? It's now a nearly a quarter off in about a year's time.

Yahoo | February 23, 2022

Is Moderna the Next Gilead or the Next Regeneron?

MRNA stock is seen purely as a Covid-19 play.

Dana Blankenhorn on InvestorPlace | February 22, 2022

Understanding Hepatitis D: 4 Questions With Professor Maria Buti

Most people are familiar with the hepatitis B (HBV) and hepatitis C (HCV) viruses that attack the liver. But not many have heard of hepatitis D (HDV), the most severe form of viral hepatitis. Peopl...

Yahoo | February 22, 2022

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To US$0.73

Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend on the 30th of March to US$0.73. This takes the...

Yahoo | February 20, 2022

Want To Collect $200 Every Month? Invest $49,334 in These 3 Stocks

You don't need to invest in stocks that pay monthly just to collect a recurring dividend income each month.

Yahoo | February 18, 2022

Charting a Career to Help Reduce Health Inequity: Porscha's Story

Dr. Porscha Showers’ route to health sciences wasn’t always a sure thing. Porscha, who grew up in Louisiana, wanted to become an attorney – despite having a mother who worked as a registered nurse ...

Yahoo | February 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7451 seconds.